Morning Overview on MSN
New Huntington’s disease treatments show promise, but caution remains
A gene therapy called AMT-130 appears to be the first treatment to slow the progression of Huntington’s disease, an inherited ...
Active exploits, nation-state campaigns, fresh arrests, and critical CVEs — this week's cybersecurity recap has it all.
Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results